Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | UCD19 CAR T cells |
| Synonyms | |
| Therapy Description |
UCD19 CAR T cells are autologous peripheral blood lymphocytes engineered to express a chimeric antigen receptor (CAR) that targets CD19, which potentially leads to killing of tumor cells expressing CD19 (NCI Drug Dictionary). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| UCD19 CAR T cells | CD19 Immune Cell Therapy 72 | UCD19 CAR T cells are autologous peripheral blood lymphocytes engineered to express a chimeric antigen receptor (CAR) that targets CD19, which potentially leads to killing of tumor cells expressing CD19 (NCI Drug Dictionary). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05535855 | Phase I | UCD19 CAR T cells | UCD19 CAR T Therapy in Adults With B-ALL and MRD Positivity in CR1 | Recruiting | USA | 0 |